Eidos Therapeutics, Inc. Common Stock
EIDX
EIDX was delisted on the 25th of January, 2021.
92 hedge funds and large institutions have $582M invested in Eidos Therapeutics, Inc. Common Stock in 2020 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 29 increasing their positions, 24 reducing their positions, and 16 closing their positions.
33,020% more call options, than puts
Call options by funds: $1.66M | Put options by funds: $5K
21% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 24
19% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 16
3% more funds holding
Funds holding: 89 → 92 (+3)
6% less capital invested
Capital invested by funds: $617M → $582M (-$34.2M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$11.7M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$11M |
| 3 |
Citigroup
New York
|
+$4.82M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
+$4.65M |
| 5 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$3.68M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$13.2M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
-$13M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$11.3M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$6.27M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$4.77M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AAMU
101
Amundi Asset Management US
Boston,
Massachusetts
| – | -$186K | -3,800 | Closed |
|
102
Ensign Peak Advisors
Salt Lake City,
Utah
| – | -$176K | -3,592 | Closed |
|
103
Group One Trading
Chicago,
Illinois
| – | -$94.6K | -2,035 | Closed |
|
|
FC
104
FORA Capital
Miami,
Florida
| – | -$94K | -1,915 | Closed |
|
|
PA
105
Parallel Advisors
San Francisco,
California
| – | -$8K | -172 | Closed |
|
|
EW
106
Evoke Wealth
Los Angeles,
California
| – | -$2.79K | -57 | Closed |
|
|
BFC
107
Bedel Financial Consulting
Indianapolis,
Indiana
| – | -$3K | -54 | Closed |
|
108
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$2K | -49 | Closed |
|
EIDX Hedge Fund Activity: Q2 2020 in Review
92 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Eidos Therapeutics, Inc. Common Stock (EIDX) for Q2 2020, worth a combined $582M — down 5.5% from $617M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new EIDX positions and 16 closed out — a net gain of 3 holders — while 29 added to existing stakes and 24 trimmed.
The largest buyer was Vanguard Group, adding an estimated $11.7M. The largest seller was Fidelity Investments, cutting an estimated $13.2M.
- 92 institutional investors held Eidos Therapeutics, Inc. Common Stock (EIDX) as of Q2 2020, up from 89 in Q1 2020.
- Funds reported $582M of Eidos Therapeutics, Inc. Common Stock stock for Q2 2020, down 5.5% quarter-over-quarter.
- 19 funds opened new Eidos Therapeutics, Inc. Common Stock positions in Q2 2020 and 16 closed out, a net change of +3 holders.
- The largest Eidos Therapeutics, Inc. Common Stock buyer in Q2 2020 was Vanguard Group, an estimated $11.7M added.
- The largest Eidos Therapeutics, Inc. Common Stock seller in Q2 2020 was Fidelity Investments, an estimated $13.2M sold.
Based on aggregated 13F filings for Q2 2020.